Back to Search
Start Over
Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants
- Source :
- The Pediatric infectious disease journal. 28(3)
- Publication Year :
- 2009
-
Abstract
- BACKGROUND: The highest rate of invasive meningococcal disease is among children under 2 years of age. There is currently no licensed quadrivalent (serogroups A, C, W-135, and Y) meningococcal glycoconjugate vaccine approved for infants. We evaluated the immunogenicity and reactogenicity of a novel quadrivalent nonadjuvanted meningococcal glycoconjugate vaccine (MenACWY-CRM) in healthy infants. METHODS: One hundred eighty infants (90 in Canada and 90 in the United Kingdom) received 2 doses of MenACWY-CRM at 2 and 4 months of age administered concomitantly with routine infant vaccines. At 12 months of age, the Canadian infants received either MenACWY-CRM or a reduced dose of a licensed meningococcal polysaccharide vaccine. In the United Kingdom, all infants received a further dose of MenACWY-CRM. The serological marker of protection was a titer of > or =1:4 using a serum bactericidal assay with human complement (hSBA). RESULTS: Two doses of MenACWY-CRM induced hSBA titers > or =1:4 in 57% (95% confidence interval [CI]: 45-67) and 50% (95% CI: 38-62) of infants against serogroup A in Canada and the United Kingdom, respectively, 93% (95% CI: 85-97) and 86% (95% CI: 46-93) against serogroup C, 95% (95% CI: 87-99) and 82% (95% CI: 71-90) against serogroup W-135, and 91% (95% CI: 82-96) and 74% (95% CI: 63-83) against serogroup Y. After a booster dose of MenACWY-CRM at 12 months, at least 94% of participants achieved hSBA titers > or =1:4 against each of the serogroups C, W-135, and Y and more than 79% against serogroup A. The vaccine was well tolerated. CONCLUSIONS: The nonadjuvanted MenACWY-CRM is immunogenic and well tolerated in infancy and could provide broad protection against meningococcal disease in this vulnerable age group.
- Subjects :
- Microbiology (medical)
Serotype
Male
Glycoconjugate
Meningococcal Vaccines
Neisseria meningitidis
Meningococcal disease
medicine.disease_cause
Adjuvants, Immunologic
medicine
Humans
Serotyping
chemistry.chemical_classification
Reactogenicity
Vaccines, Conjugate
biology
business.industry
Immunogenicity
Infant
medicine.disease
Virology
Antibodies, Bacterial
Vaccination
Meningococcal Infections
Infectious Diseases
Treatment Outcome
chemistry
Pediatrics, Perinatology and Child Health
Immunology
biology.protein
Female
Antibody
business
Immunologic Memory
Subjects
Details
- ISSN :
- 08913668
- Volume :
- 28
- Issue :
- 3
- Database :
- OpenAIRE
- Journal :
- The Pediatric infectious disease journal
- Accession number :
- edsair.doi.dedup.....d854cccf309ea3a8e61d91b41125ba73